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Beta-amyloid (Ab) oligomers contribute to the pa-
thophysiology of Alzheimer disease (AD), and me-
tabotropic glutamate receptor 5 (mGluR5) has
been shown to act as a receptor for both Ab oli-
gomers and cellular prion proteins. Furthermore,
the genetic deletion of mGluR5 in an APPswe/
PS1DE9 mouse model of AD improves cognitive
function and reduces Ab plaques and Ab oligomer
concentrations. Here, we show that chronic admin-
istration of the orally bioavailable mGluR5-selective
negative allosteric modulator CTEP, which is similar
in structure, potency, and selectivity to Basimglur-
ant (RO4917523), which is currently in phase II clin-
ical development for major depressive disorder and
fragile X syndrome, reverses cognitive decline in
APPswe/PS1DE9 mice and reduces Ab plaque
deposition and soluble Ab oligomer concentrations
in both APPswe/PS1DE9 and 3xTg-AD male mice.
These findings suggest that CTEP or its analogue
Basimglutant might potentially be an effective ther-
apeutic for the treatment of AD patients.
INTRODUCTION
Alzheimer disease (AD) is the most prevalent neurodegenerative
disease, and the predominant neurotoxic species in the brains
of AD patients is beta-amyloid (Ab) protein, which is formed by
the sequential cleavageof amyloid precursor protein (APP) (Citron
et al., 1996; Kamenetz et al., 2003). These oligomers have been
shown to be the most harmfully correlated with AD pathogenesis
(McGowan et al., 2005; Shankar et al., 2008). Metabotropic gluta-
mate receptor 5 (mGluR5) is a member of the G protein-coupled
receptor (GPCR) superfamily that is activated by glutamate to
couple to the heterotrimeric G protein Gaq/11, resulting in the
downstream second messenger-dependent release of intracel-
lular Ca2+ that has been linked to a number of neurodegenerativeCell
This is an open access article unddiseases (Ribeiro et al., 2010). Ab oligomers and cellular prion
protein (PrPC) interact with mGluR5 to cause the release of Ca2+
from intracellular stores, thusdisruptingnormal neuronal signaling
and function (Renner et al., 2010; Sokol et al., 2011; Um et al.,
2013;Haas et al., 2014). Thegenetic deletion ofmGluR5 improves
AD pathogenesis and cognitive decline in the APPswe/PS1DE9
mouse model of AD (Hamilton et al., 2014). Preclinical trials in
fragile X syndrome and major depressive disorder with 2-chloro-
4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)
ethynyl) pyridine (CTEP) suggest that this mGluR5-selective
allosteric modulator may be effective for the treatment of AD
(Lindemann et al., 2011, 2015; Michalon et al., 2012). CTEP has
high in vivo potency and is an orally bioavailable, brain-permeant,
mGluR5-negative allostericmodulator ofmGluR5; it has a half-life
of 18 hr in vivo, allowing once a day administration that is effective
for the treatment of fragile X in adult mice (Lindemann et al., 2011;
Michalon et al., 2012). Moreover, CTEP is highly selective for
mGluR5 versus more than 100 GPCR targets tested (Lindemann
et al., 2011).
In the present study, we tested whether acute and/or chronic
treatment with CTEP improved cognitive performance and
reduced Ab pathology in APPswe/PS1DE9 male mice. We found
that chronic, but not acute, administration of CTEP by intraperito-
neal injection rescuesmemory deficits in novel object recognition,
Morris water maze (MWM), and reversal MWM (RMWM) memory
paradigms in APPswe/PS1DE9 mice. Chronic CTEP treatment
also significantly reduced Ab oligomer concentrations and plaque
formation in both APPswe/PS1DE9 and 3xTg-AD mouse models
of AD. Our data provide further evidence of a central role for
mGluR5 in AD, and they highlight the potential for repurposing
the CTEP analogue Basimglurant as a treatment for AD.
RESULTS
Chronic, but Not Acute, Treatment with CTEP Rescues
Memory Loss
To test whether CTEP treatment would ameliorate the behavioral
and pathological phenotypes observed in AD mouse models,
wild-type C57Bl/6, APPswe/PS1DE9, and 3xTg-AD mice male
mice were raised to 9 months of age and treated with eitherReports 15, 1859–1865, May 31, 2016 ª 2016 The Author(s). 1859
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Chronic, but Not Acute, Adminis-
tration of CTEP Rescues Recognition Mem-
ory in APPswe/PS1DE9 and 3xTg-AD Mice
(A) The recognition index is shown for acute
(5-day) drug administration, when mice explore
two identical objects and one novel versus familiar
object in saline-treated C57Bl/6 mice (n = 11),
CTEP-treated C57Bl/6 mice (2 mg/kg; n = 12),
saline-treated APPswe/PS1DE9 mice (n = 6), and
CTEP-treated APPswe/PS1DE9 mice (2 mg/kg;
n = 10).
(B) The same as (A) is shown again following
chronic (10- to 12-week) drug treatment in saline-
treated C57Bl/6 mice (n = 10), CTEP-treated
C57Bl/6 mice (n = 12), saline-treated APPswe/
PS1DE9 mice (n = 7), and CTEP-treated APPswe/
PS1DE9 mice (n = 10).
(C) The recognition index is shown for acute
(5-day) drug administration, when mice explore
two identical objects and one novel versus familiar
object in saline-treated C57Bl/6 mice (n = 11),
CTEP-treated C57Bl/6 mice (2 mg/kg; n = 11),
saline-treated 3xTg-AD mice (n = 7), and CTEP-
treated 3xTg-AD mice (2 mg/kg; n = 10).
(D) The same as (C) is shown again following
chronic (10- to 12-week) drug treatment in saline-
treated C57Bl/6 mice (n = 12), CTEP-treated C57Bl/6 mice (n = 12), saline-treated 3xTg-ADmice (n = 8), and CTEP-treated 3xTg-AD mice (n = 9). Data represent
themean ±SEM. Statistical significance is assessed by two-way ANOVA followed by Newman-Keuls multiple comparisons post hoc test (*p < 0.05 versus saline-
treated mice).saline or CTEP (2 mg/kg) by intraperitoneal injection every 48 hr
for a duration of 3 months. This drug dose was chosen based on
the effective CTEP concentration utilized to treat fragile X mice
(Michalon et al., 2012).Micewere first tested for the acute effects
of drug treatment on cognitive behavior 5 days following the
initiation of drug treatment using a novel object recognition test
for recognition/episodic memory. The ANOVA for the recognition
index (presence in novel area) indicated that there were
differences for APPswe/PS1DE9 versus C57Bl/6 mouse types
(F [1, 34] = 13.00; p = 0.001) (Figure 1A). In contrast, analysis
of the recognition scores for chronically saline- and CTEP-
treated C57Bl/6 and APPswe/PS1DE9 mice revealed no signifi-
cant differences between groups (F [1, 37] = 2.55; p = 0.12)
(Figure 1B). However, as a clear a priori hypothesis had been
made, follow-up statistical testing revealed that chronically
CTEP-treated APPswe/PS1DE9 mice exhibited recognition
scores that were significantly higher than those of saline-treated
APPswe/PS1DE9 mice. Similarly, there were significant
differences in the recognition indexes for C57Bl/6 and 3xTg-
AD mice that were acutely treated with and without CTEP
(F [1, 28] = 10.56; p = 0.003) (Figure 1C). Chronic saline CTEP
treatment of C57Bl/6 and3xTg-AD mice did not result in signifi-
cant differences between groups (F [1, 33] = 2.52; p = 0.12),
but the recognition scores for chronically CTEP 3xTg-AD mice
were significantly higher than those of saline-treated 3xTg-AD
mice (Figure 1D).
Wild-type (C57Bl/6) and APPswe/PS1DE9 mice subse-
quently were tested in the MWM on days 6–10, which involved
exposure to the maze for 16 90-s trials over 4 days during the
acquisition phase (four trials per day), followed by a 60-s probe
trial on day 5. Then 1 day after the completion of the MWM,1860 Cell Reports 15, 1859–1865, May 31, 2016RMWM training commenced using the same protocol, except
that the location of the platform was moved. For both tests
we assessed escape latency, path length, and swim speed.
In the MWM, latency to find the platform and the path length
largely paralleled each another, and, in both cases, perfor-
mance varied as a function of the strain 3 drug 3 trial treat-
ment (F[3, 72] = 10.95 and 11.67; p values <0.001, respectively,
for acutely saline- and CTEP-treated wild-type and APPswe/
PS1DE9 mice) (Figures 2A and 2B). The follow-up tests indi-
cated, as shown in Figures 2A and 2B, that in wild-type mice
the CTEP treatment modestly reduced response latencies
and path length on the initial day of testing. In saline-treated
APPswe/PS1DE9 mice, performance on these measures did
not differ from that of similarly treated wild-type mice. However,
among the APPswe/PS1DE9 mice, the CTEP treatment signifi-
cantly increased response latencies and path length relative to
both the saline-treated APPswe/PS1DE9 mice and the wild-
type mice treated with CTEP. The swim speed of mice declined
over days (F[3, 105] = 11.24; p < 0.001) and varied as a function
of the drug treatment 3 days interaction (F[3, 105] = 4.65;
p < 0.01). The follow-up tests indicated that swim speed in
CTEP mice was somewhat faster than in saline-treated ani-
mals, although the magnitude of this effect was small (Fig-
ure 2C). In essence, the CTEP treatment modestly enhanced
initial performance in wild-type mice, but it disrupted perfor-
mance in the APPswe/PS1DE9 mice. There were no observed
differences between mouse groups (F[3, 43] = 1.59; p = 0.21)
for the time spent in the target quadrant of the maze following
the removal of the platform (Figure 2D).
The analyses of MWM performance resulting from chronic
CTEP treatment revealed outcomes that were distinct from
Figure 2. Performance of APPswe/PS1DE9
Mice in the MWM following Either Acute or
Chronic Treatment with CTEP
(A–D) Shown are the results obtained for MWM
acquisition phase for (A) escape latency, (B) dis-
tance traveled, (C) swim speed, and (D) time spent
in the target quadrant during the probe trial for
C57Bl/6 and APPswe/PS1DE9 mice acutely
treated with either saline or CTEP.
(E–H) Shown are the results obtained for MWM
acquisition phase for (E) escape latency, (F) dis-
tance traveled, (G) swim speed, and (H) time spent
in the target quadrant during the probe trial for
C57Bl/6 and APPswe/PS1DE9 mice chronically
treatedwith either saline or CTP for 10weeks. Data
are shown for saline-treated C57Bl/6 (wild-type
[WT]) mice (n = 12), CTEP-treated C57Bl/6 (WT)
mice (n = 13), saline-treated APPswe/PS1DE9
(APPswe) mice (n = 9), and CTEP-treated APPswe/
PS1DE9 (APPswe) mice (n = 12). Data represent
the mean ± SEM. Statistical significance is
considered p < 0.05, represented by *p < 0.05 and
**p < 0.01; differences are between mice groups
when compared to saline-treated wild-type mice.
Statistical significance is assessed by two-way
ANOVA followed by Newman-Keuls multiple
comparisons post hoc test (*p < 0.05).the effects attributable to acute CTEP administration (Figures
2F–2H). In this instance, the ANOVA revealed that escape la-
tencies, path length, and swim speed varied as a function of
the strain 3 CTEP 3 trial treatment interaction (F[3, 95] =
17.93, 18.69, and 3.99; p values <0.001, respectively) (Figures
2E–2G). The follow-up comparisons of the simple effects of sig-
nificant interactions, depicted in Figures 3E and 3F, indicated
that for wild-type mice the CTEP treatment disrupted escape
latencies and increased path length on the initial 2 days of
testing relative to saline-treated mice. The APPswe/PS1DE9
mice treated with saline exhibited significantly longer escape
latencies and greater path lengths than did similarly treated
wild-type mice. However, unlike the effects seen in the wild-
type mice, the CTEP treatment provoked markedly shorter
escape latency and shorter path lengths than did APPswe/
PS1DE9 mice treated with saline or wild-type mice that
received CTEP. Moreover, significant differences were
observed between mouse groups (F[3, 41] = 3.243; p < 0.05)
for the time spent in the target quadrant of the maze followingCell Rthe removal of the platform. Saline-
treated APPswe/PS1DE9 mice spent
the least time in the target quadrant
when compared to the other mouse
groups (Figure 3H). Taken together,
these data indicated that long-term
CTEP treatment prevents the develop-
ment of spatial memory impairment in
APPswe/PS1DE9 mice.
For the RMWM, among mice that
received acute CTEP treatment the
escape latencies, path length, and swimspeed during the reversal did not vary as a function of the strain,
drug, or trial for any interactions involving these variables (Fig-
ures 3A–3C). There also were no observed differences between
mouse groups (F[3, 42] = 1.103; p = 0.36) for the time spent in the
target quadrant of themaze following the removal of the platform
(Figure 3D). However, a very different picture emerged in
response to the chronic treatment condition. In this instance, la-
tencies and path length varied with the strain 3 CTEP 3 Trial
interaction (F [3, 126] = 7.07 and 10.7; p < 0.001) (Figures 3E
and 3F), but swim speed did not vary with the treatments (Fig-
ure 3G). Curiously, APPswe/PS1DE9 mice chronically treated
with saline exhibited a marked deterioration of performance
over days. This was obviously very different from the perfor-
mance seen in acutely treated mice, although it’s not certain
whether this was a result of mice being 3 months older or the
stress experienced with repeated injections. Similar to what
was observed in the MWM, saline-treated APPswe/PS1DE9
mice spent the least time in the target quadrant when compared
to the other mouse groups (F[3, 42] = 7.55; p < 0.001) (Figure 3H).eports 15, 1859–1865, May 31, 2016 1861
Figure 3. Performance of APPswe/PS1DE9
Mice in the RMWM following Either Acute
or Chronic Treatment with CTEP
(A–D) Shown are the results obtained for RMWM
acquisition phase for (A) escape latency, (B) dis-
tance traveled, (C) swim speed, and (D) time spent
in the target quadrant during the probe trial for
C57Bl/6 and APPswe/PS1DE9 mice acutely
treated with either saline or CTEP.
(E–H) Shown are the results obtained for RMWM
acquisition phase for (E) escape latency, (F) dis-
tance traveled, (G) swim speed, and (H) time spent
in the target quadrant during the probe trial for
C57Bl/6 and APPswe/PS1DE9 mice chronically
treated with either saline or CTEP for 10 weeks.
Data are shown for saline-treated C57Bl/6 (WT)
mice (n = 12), CTEP-treated C57Bl/6 (WT)
mice (n = 13), saline-treated APPswe/PS1DE9
(APPswe) mice (n = 9), and CTEP-treated APPswe/
PS1DE9 (APPswe) mice (n = 12). Data represent
the mean ± SEM. Statistical significance is
considered p < 0.05, represented by *p < 0.05;
differences are between mice groups when
compared to saline-treated wild-type mice. Sta-
tistical significance is assessed by two-way
ANOVA followed by Newman-Keuls multiple
comparisons post hoc test (*p < 0.05).Taken together, these data indicated that long-term CTEP treat-
ment prevents the development of spatial memory impairment in
APPswe/PS1DE9 mice.
Chronic Treatment with CTEP Reduces Ab
The accumulation of Ab in APPswe/PS1DE9 mice occurs as
early as 3 months of age (Lalonde et al., 2005). Therefore, to
determine whether the improved cognitive performance of
the APPswe/PS1DE9 and 3xTg-AD mice was associated with
a reduction in AD pathology, we assessed whether Ab plaques
and Ab oligomers were reduced in CTEP-treated APPswe/
PS1DE9 and 3xTg-AD mice (Figures 4A and 4B). We found
that Ab plaque number was reduced in coronal cortical brain
slices derived from both APPswe/PS1DE9 (p < 0.0001)
and 3xTg-AD (p < 0.001) mice treated for 3 months with
CTEP when compared to mice treated with saline (Figure 4C).
Similarly, Ab plaque number was reduced in coronal hippo-
campal brain slices derived from both APPswe/PS1DE9 (p <
0.001) and 3xTg-AD (p = 0.001) mice treated for 3 months1862 Cell Reports 15, 1859–1865, May 31, 2016with CTEP when compared to mice
treated with saline (Figure 4D).
To assess the effect of chronic CTEP
treatment on Ab oligomer load in
APPswe/PS1DE9 and 3xTg-AD mice,
whole brains from saline- and CTEP-
treated mice were analyzed for Ab oligo-
mers using a sandwich ELISA assay.
We found a statistically significant differ-
ence in Ab oligomer concentrations in
saline- and CTEP-treated wild-type and
APPswe/PS1DE9 mice (F[3, 16] = 46.09;p < 0.001) (Figure 4E). Ab oligomer concentrations were 4.0- ±
0.5-fold higher in saline-treated APPswe/PS1DE9 (p < 0.001)
mice compared to saline-treated wild-type controls, and CTEP
treatment significantly reduced Ab oligomer concentrations in
APPswe/PS1DE9 mice (p < 0.001). However, Ab oligomer con-
centrations were higher in both wild-type and APPswe/
PS1DE9 mice treated with CTEP compared to saline-treated
wild-typemice (p < 0.05). Similarly, we found a statistically signif-
icant difference in Ab oligomer concentrations in saline- and
CTEP-treated wild-type and 3xTg-AD mice (F[3, 16] = 10.92;
p = 0.001) (Figure 4F). Ab oligomer concentrations were 2.3- ±
0.5-fold higher in saline-treated 3xTg-AD (p < 0.001) mice
compared to saline-treated wild-type controls, and CTEP treat-
ment significantly reduced Ab oligomer concentrations in
3xTg-AD mice (p < 0.01). However, Ab oligomer concentrations
were no different in wild-type and 3xTg-AD mice treated with
CTEP when compared to saline-treated wild-type mice. Thus,
pharmacological blockade of mGluR5 not only improves the
cognitive performance of APPswe/PS1DE9 mice but also it
Figure 4. Ab Formation and Plaque Number
Are Reduced in APPswe/PS1DE9 and
3xTg-AD Mice following Chronic Treatment
with CTEP
(A) Representative images of Ab plaques from the
cortex and hippocampus of APPswe/PS1DE9
mice treated with either saline or CTEP for
3 months are shown. Scale bar, 100 mm.
(B) Representative images of Ab plaques from the
cortex and hippocampus of 3xTg-AD mice treated
with either saline or CTEP for 3 months are shown.
Scale bar, 100 mm.
(C) The graph shows the number of plaques
counted in 9003 900-mm regions of interest in the
cortex in coronal brain slices from APPswe/
PS1DE9 and 3xTg-AD mice chronically treated
with either saline or CTEP. Data represent the
mean ± SEM of four to six independent experi-
ments. Statistical significance is assessed by un-
paired t test.
(D) The graph shows the number of plaques
counted in 9003 900-mm regions of interest in the
hippocampus in coronal brain slices from
APPswe/PS1DE9 and 3xTg-AD mice chronically
treated with either saline or CTEP. Data represent
the mean ± SEM of four to six independent ex-
periments. Statistical significance is assessed by
unpaired t test.
(E) The whole-brain Ab oligomer (ng/mg protein)
concentrations in 12-month-old C57Bl/6 (WT) and
APPswe/PS1DE9 (APPswe) mice chronically
treated with either saline or CTEP. Data represent
the mean ± SEM of four independent experiments.
Statistical significance is assessed by one-way
ANOVA and Tukey’s multiple comparison post hoc
test (*p < 0.001).
(F) The whole-brain Ab oligomer (ng/mg protein)
concentrations in 12-month-old C57Bl/6 (WT) and
3xTg-ADmice chronically treatedwith either saline
or CTEP. Data represent the mean ± SEM of four
independent experiments. Statistical significance
is assessed by one-way ANOVA and Tukey’s
multiple comparison post hoc test (**p < 0.001 and
*p < 0.05 versus saline control).reduces AD-like neuropathology in two different AD mouse
models.
DISCUSSION
AD is themost common cause of dementia in adults and involves
a loss of memory and other cognitive abilities as the conse-
quence of neurodegeneration, mediated in part by both soluble
Ab oligomers and neurofibrillary tangles that alter synaptic
signaling by promoting synaptic loss (Lesne´ et al., 2006).We pre-
viously reported that genetic deletion of mGluR5 in the APPswe/
PS1DE9 mouse model of AD results in the amelioration of cogni-
tive decline and reduces Ab plaque deposition and soluble Ab
oligomer concentrations (Hamilton et al., 2014). In this study,
we provide evidence that the selective blockade of mGluR5 ac-
tivity with the high-affinity, orally bioavailable, negative allosteric
modular CTEP also improves cognitive behavioral performance
in an APPswe/PS1DE9 AD mouse model. This is paralleled bya CTEP-dependent reduction in the development of AD-like
neuropathology in both APPswe/PS1DE9 and 3xTg-AD mouse
cortical and hippocampal brain regions.
This study extends our previous work demonstrating that the
genetic knockout of mGluR5 corrects spatial memory loss in
APPswe/PS1DE9 mice (Hamilton et al., 2014). We now show
that prolonged administration of CTEP not only rescues spatial
memory deficits but also corrects deficits in episodic and recog-
nition memory that are manifested earlier in APPswe/PS1DE9
mouse disease progression. The observation that genetic dele-
tion ofmGluR5 corrects spatial memory impairment and reduces
Ab oligomer levels potentially could be dismissed as simply be-
ing the consequence of adaptations that may occur in the
absence of mGluR5 during brain development. However, our
findings that pharmacological intervention with CTEP in fully
developed mice at 9 months prevents the progression and/or re-
verses memory impairment in APPswe/PS1DE9 mice suggests
that this outcome is not the consequence of a developmentalCell Reports 15, 1859–1865, May 31, 2016 1863
adaptation process. Rather, the pharmacological data indicate
that mGluR5 is a centrally important contributor to AD-like dis-
ease cognitive impairment and pathology and that blockade of
mGluR5 signaling with a negative allosteric modulator is ne-
uroprotective. This conclusion is further substantiated by the
observation that MTEP treatment of APPswe/PS1DE9 mice
also improves performance in the MWM and can result in
improved long-term potentiation (LTP) and reduced long-term
synaptic depression (LTD) (Shankar et al., 2008; Li et al., 2009;
Rammes et al., 2011; Um et al., 2013). Moreover, antagonists
of mGluR5 prevent the block of LTP mediated by Ab oligomers
(Wang et al., 2004). Thus, it is possible that blockade of mGluR5
with CTEP improves cognition by reducing mGluR5-mediated
LTD induced by Ab oligomers, and the reduction of AD pathology
may occur as a consequence of reduced mGluR5-dependent
APP translation.
Of particular mechanistic interest to AD disease progression is
the finding that both genetic deletion and chronic pharmacolog-
ical blockade reduce both Ab oligomer levels and the formation
of Ab plaques (Hamilton et al., 2014). This surprising and unex-
pected result indicates that mGluR5 signaling contributes
directly to the establishment of AD-like disease pathology in
APPswe/PS1DE9 mice. It is reported that Ab oligomers promote
mGluR5 clustering at synapses, resulting in increased activation
of Ca2+ signaling, and Ab oligomer-activated mGluR5 signaling
may be associated with accentuated LTD (Renner et al., 2010;
Hu et al., 2014). Thus, it is likely that CTEP not only functions
to block glutamate-mediated activation of mGluR5 but also
pathological Ab oligomer-mediated mGluR5 signaling contrib-
utes directly to AD-like pathology linked to impaired cognitive
behavior, as we observe an amelioration of AD pathology in
both APPswe/PS1DE9 and 3xTg-AD mice. This suggests
that the ongoing activation of mGluR5 by Ab42 oligomers may
result in a growing pathological insult that can be prevented by
long-term mGluR5 antagonism. Thus, although under normal
physiological conditions mGluR5 blockade is not desirable, un-
der pathophysiological conditions where mGluR5 is engaged
by a non-physiological ligand (Ab oligomers), mGluR5 antago-
nism results in a beneficial physiological effect by reversing an
undesired pathophysiological signal.
Surprisingly, either mGluR5 antagonism or knockout corrects
the cognitive impairment normally observed in APPswe/PS1DE9
mice, despite previous observations that mGluR5 contributes to
processes associated with memory and learning (Lu et al., 1997;
Hamilton et al., 2014; Hu et al., 2014). However, consistent with
the fact that mGluR5 is important for memory and learning, we
find that CTEP treatment does cause a discernible impairment
in spatial memory tasks in the MWM in wild-type mice. Thus, un-
der normal physiological conditions, it is likely that mGluR5
blockade is not desirable. But, under pathophysiological condi-
tions where mGluR5 is engaged by a non-physiological ligand,
such as Ab oligomers, antagonism of the receptor likely results
in a beneficial physiological effect that antagonizes the outcome
of a pathophysiological signal.
In conclusion, CTEP is currently in pre-clinical development
for the treatment of major depression disorder and fragile
X syndrome, and it has been utilized successfully to treat the
symptoms of preclinical mouse models of major depression dis-1864 Cell Reports 15, 1859–1865, May 31, 2016order and fragile X syndrome (Michalon et al., 2012; Lindemann
et al., 2015). We have now provided both genetic and pharmaco-
logical evidence that mGluR5 is an ideally suited target to
ameliorate the clinical progression of AD. Thus, based on the
desirable bioavailability and selectivity of CTEP, and that its
analogue Basmiglurant is in phase II clinical trials, we suggest
mGluR5 NAMs are ideal small molecule candidate drug for re-
purposing potential for clinical use in the treatment of AD.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures are provided in the Supplemental Experi-
mental Procedures.
Animals
APPswe/PS1DE9 and 3xTg-AD mice were purchased from the Jackson
Laboratory. All animal experimentswere conducted in accordancewith theUni-
versity of Western Ontario and University of Ottawa animal care committees.
Novel Object Recognition
Time spent exploring each object was recorded. Mice were considered to
be exploring an object if their snout was within 1 cm of the object. Then 3 hr
after first exposure, one object was replaced with a novel object and mice
were returned to the maze for 10 min. Data were interpreted using a recogni-
tion index, which was the percentage of time exploring the familiar object
versus the novel object.
MWM and RMWM
Acquisition Phase, Days 1–4
Mice were trained over 4 consecutive days, four trials per day, with 15-min in-
tervals between trials. Mice were randomly started from four equally spaced
points around the pool, across each of the four daily trials. Animals were given
90 s to find the escape platform; if they failed to do so, they were guided to the
platform where they remained for 30 s before being returned to their home
cage. Swim speed and escape latency were recorded and statistical analysis
was performed using GraphPad Prism.
Probe Trial, Day 5
The probe trial was performed to assess spatial memory by removing the
platform and recording the time the mice spent in the target quadrant.
RMWMwas initiated 24 hr after the completion of MWM, and it was performed
using the same paradigm as MWM, with 4 days acquisition and probe trial. In
the RMWM task, the platform was moved to a new location. Analysis was
performed as described for MWM.
Ab Immunohistochemistry
Brains were coronally sectioned to include both the cortex and hippocampus,
and analysis was performed on 40-mm free-floating sections using a peroxi-
dase-based immunostaining protocol. Sections were incubated in primary
antibody for Ab overnight at 4C, washed, incubated in biotinylated antibody,
and then incubated in an avidin biotin enzyme reagent. Sections weremounted
on slides and visualized with a Zeiss LSM-510 META multiphoton laser-scan-
ning microscope with a Zeiss 103 lens, using representative 900 3 900-mm
areas of cortex and hippocampus.
Determination of Ab Oligomer Concentration by Sandwich ELISA
In brief, brains were dissected into right and left hemispheres, with one hemi-
sphere used to analyze oligomeric Ab. Quantification of Ab oligomers, in
12-month-old fresh mouse brains, was performed using a sandwich ELISA
kit (KHB3491, Thermo Fisher Scientific) according to the manufacturer’s
instructions.
Statistical Analyses
Data in the recognition test were analyzed by 2 (strain) 3 2 (drug treatment),
whereas the dependent outcomes for the MWM test were analyzed by a
mixed-measures ANOVA.
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